MedPath

Comparing efficacy of different preparations of Tranexamic Acid in the management of melasma

Phase 3
Conditions
Health Condition 1: L811- Chloasma
Registration Number
CTRI/2023/10/058614
Lead Sponsor
Ashutosh Trivedi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All adult patients diagnosed with facial melasma

Exclusion Criteria

Children < 18 years of age, pregnant or nursing women or women planning pregnancy during the duration of trial.

Patients with Extra - facial melasma

Patient unwilling to give consent to be part of trial.

Current use of oral or injectable contraceptives, hormone replacement therapy, blood thinning medications, photosensitizing drugs or drugs known to cause hyperpigmentation of skin.

Current or previous use of any medical treatment (topical or oral) or cosmetic procedure (chemical peel, Laser, Dermabrasion) for melasma within 9 months of study enrollment.

History of thromboembolic disease such as deep vein thrombosis (DVT), >2 spontaneous abortions, pulmonary embolism or cerebral thrombosis, stroke or subarachnoid haemorrhage.

Family history of thromboembolic disease.

Smoking, tobacco use.

Hypersensitivity to tranexamic acid or sunscreen ingredients.

Abnormal bleeding profile (PT INR, Bleeding Time, Clotting Time).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath